VHL and synovial sarcoma: When considering patients with no VHL mutation, deletion or hyper-methylation (n=11, 10.8%), it appeared that their outcome was significantly worse both for PFS and RCC-SS than patients having at least one VHL alteration (log-rank test, P=0.02; Figure 1B).